SCHEMBL4324296

SCHEMBL4324296

CN(C)CCN(N=Cc1ccc(-c2ccc(C(F)(F)F)cc2Cl)o1)C(N)=S

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.43
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 5/20 0.40
MEN1 O00255 3/20 0.40
LMNA P02545 3/20 0.40
KMT2A Q03164 3/20 0.40
PTPN12 Q05209 1/20 0.40
NPFFR1 Q9GZQ6 3/20 0.38
NPFFR2 Q9Y5X5 3/20 0.38
MAPT P10636 5/20 0.37
NPSR1 Q6W5P4 3/20 0.37
HPGD P15428 2/20 0.37
MAPK1 P28482 3/20 0.36
MITF O75030 1/20 0.36
HTT P42858 1/20 0.36
PKM P14618 1/20 0.35
ALOX12 P18054 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4333009 0.93 PTPN1 (0.51) PTPN1ALDH1A1KDM4EMEN1LMNA
SCHEMBL4326297 0.83 KDM4E (0.42) ALDH1A1KDM4EMEN1LMNAKMT2A
SCHEMBL4344446 0.83 PTPN1 (0.51) PTPN1ALDH1A1KDM4EMEN1LMNA
SCHEMBL4451545 0.81 PTPN1 (0.50) PTPN1ALDH1A1KDM4EMEN1LMNA
SCHEMBL4331665 0.78 KMT2A (0.56) ALDH1A1KDM4EMEN1LMNAKMT2A
SCHEMBL4331661 0.78 KMT2A (0.56) ALDH1A1KDM4EMEN1LMNAKMT2A
SCHEMBL4324299 0.78 PTPN1 (0.56) PTPN1ALDH1A1KDM4EMEN1LMNA
SCHEMBL4324292 0.78 PTPN1 (0.56) PTPN1ALDH1A1KDM4EMEN1LMNA
SCHEMBL4341378 0.77 MAPT (0.48) ALDH1A1KDM4EMEN1LMNAKMT2A
SCHEMBL4343385 0.76 ALDH1A1 (0.69) PTPN1ALDH1A1KDM4EMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 PTPN1 476/4885ALDH1A1 1459/4885KDM4E 3010/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 PTPN1 525/4885ALDH1A1 1173/4885KDM4E 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.